Latest From AlphaVax Inc.
The latest Ebola epidemic, which the WHO says has now claimed more than 9,600 lives, has focused attention on the long-term need for a prophylactic vaccine to prevent future outbreaks of this size.
Novartishas acquired an investigational cytomegalovirus (CMV) vaccine programme from the US-based vaccine developer AlphaVax for $20 million.
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- AlphaVax Inc.
- Senior Management
Tim C Gupton, CFO
Janice A Kimpel , PhD, VP, Bus. Dev.
Jonathan Smith, CSO
- Contact Info
Phone: (919) 595-0400
2 Triangle Dr.
P.O. Box 110307 Research Triangle Park, NC 27709-0307
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.